Modelling of late side-effects following cranial proton beam therapy

2021 ◽  
Vol 157 ◽  
pp. 15-23
Author(s):  
Almut Dutz ◽  
Armin Lühr ◽  
Linda Agolli ◽  
Rebecca Bütof ◽  
Chiara Valentini ◽  
...  
2019 ◽  
Vol 58 (6) ◽  
pp. 916-925 ◽  
Author(s):  
Almut Dutz ◽  
Linda Agolli ◽  
Michael Baumann ◽  
Esther G. C. Troost ◽  
Mechthild Krause ◽  
...  

1996 ◽  
Vol 40 ◽  
pp. S56
Author(s):  
E. Weiss ◽  
H. Arnold-Bofinger ◽  
N. Weidner ◽  
P. Hirnle ◽  
M. Bamberg

1995 ◽  
Vol 31 ◽  
pp. S236
Author(s):  
V. Fayrel ◽  
Th. Schmitt ◽  
J.L. Stephan ◽  
D. Guyotat ◽  
G. Puel ◽  
...  

2007 ◽  
Vol 13 (4) ◽  
pp. 187-189 ◽  
Author(s):  
Bernardo Moreira ◽  
Sigride Thomé-Souza ◽  
Kette Valente

Lamotrigine (LTG) is a generally well-tolerated antiepileptic drug with broad-spectrum efficacy in several forms of partial and generalized epilepsy. Adverse effects of lamotrigine are usually associated with introduction and titration. This risk increases in children and in the co-medication with valproate. Herein, we report four patients with late adverse-effects, under the co-medication valproate and LTG, not related to drug introduction or titration. This study demonstrates that late side-effects without apparent etiology in children, adolescents and adults in chronic use of LTG, especially when associated to VPA, led to a diagnostic investigation, sometimes invasive. It must be emphasized that, due to the excellent seizure control, the authors opted for drug decrease instead of drug withdrawal, as previously done. Studies on late adverse effects are scarce, but physicians must be aware of these risks.


Author(s):  
R Rupprecht ◽  
A Lippold ◽  
C Auras ◽  
G Bramkamp ◽  
C Breitkopf ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document